Sagimet Biosciences Announces Pricing of $175.0 Million Underwritten Offering of Series A Common Stock

Rhea-AI Summary

Sagimet Biosciences (Nasdaq: SGMT) priced an underwritten offering of 29,166,700 Series A common shares at $6.00 per share, for gross proceeds of approximately $175.0 million. The offering is expected to close on or about April 28, 2026, subject to customary conditions.

Proceeds are intended to fund a Phase 3 denifanstat acne trial, advance TVB-3567 to Phase 2 topline results, support a topical FASN inhibitor IND submission, and provide general corporate funding; the company expects cash to fund acne programs through 2028.

Positive

• Gross proceeds of $175.0 million
• Financing expected to fund acne programs through 2028
• Proceeds allocated to Phase 3 denifanstat and Phase 2 TVB-3567

Negative

• Issuance of 29,166,700 shares implies shareholder dilution
• Net proceeds smaller after underwriting discounts, commissions and expenses

News Market Reaction – SGMT

+38.57% 83.4x vol

39 alerts

+38.57% Session close to close

+49.7% Peak in 3 hr 10 min

$304.34M Market Cap

83.4x Rel. Volume

In the Apr 27 session, SGMT gained 38.57%, reflecting a significant positive market reaction. Argus tracked a peak move of +49.7% during that session. Our momentum scanner triggered 39 alerts that day, indicating elevated trading interest and price volatility. Trading volume was exceptionally heavy at 83.4x the daily average, suggesting very strong buying interest.

Data tracked by StockTitan Argus on the day of publication.

Market Context

The stock surged +38.6% in the session following this news. A strong positive reaction aligns with t...

Analysis

The stock surged +38.6% in the session following this news. A strong positive reaction aligns with the company’s strategy of using equity capital to fund late-stage acne development and FASN pipeline progress. However, the underwritten sale of 29,166,700 shares at $6.00 and prior insider net selling highlight dilution and supply overhang risks. Historical news flow has produced mixed price responses, suggesting enthusiasm could moderate as the new shares integrate into trading.

Key Figures

Offering price: $6.00 per share Shares offered: 29,166,700 shares Gross proceeds: $175.0 million +4 more

7 metrics

Offering price $6.00 per share Underwritten Series A common stock offering

Shares offered 29,166,700 shares Series A common stock in underwritten offering

Gross proceeds $175.0 million Before underwriting discounts and expenses

Phase 3 trial Phase 3 Planned denifanstat acne trial funded by proceeds

Phase 2 topline Phase 2 TVB-3567 development funded to topline results

Expected closing date April 28, 2026 Anticipated closing of underwritten offering

Program funding horizon Through 2028 Expected funding of acne programs with offering proceeds

Historical Context

5 past events · Latest: Apr 20 (Positive)

Pattern 5 events

Date	Event	Sentiment	24h Move	Catalyst
Apr 20	Management change	Positive	-0.5%	New Chief Medical Officer appointed while prior CMO moves to advisory role.
Apr 06	Clinical data update	Positive	-3.4%	Phase 2b MASH data presentations and inducement stock option grant to new hire.
Mar 11	Earnings and pipeline	Positive	+3.8%	2025 results, $113.1M cash, and multiple trial and regulatory milestones.
Feb 25	Investor conferences	Neutral	+3.5%	Participation in three March investor conferences with webcast access.
Feb 05	Investor conferences	Neutral	-10.5%	Announcement of two February healthcare conferences with 90-day webcasts.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Stock reactions to news have been mixed, with several positive updates met by negative moves, and some neutral conference news seeing large swings.

Recent Company History

Over recent months, Sagimet has reported 2025 financials with a $113.1M cash balance and advancing FASN programs, announced multiple investor conference participations, and disclosed management changes including a new Chief Medical Officer. Price reactions have varied: earnings on Mar 11, 2026 saw a positive move, while scientific and management updates in April drew mild declines. The current offering follows this sequence of capital and clinical planning steps.

Key Terms

underwritten offering, series a common stock, phase 3 clinical trial, phase 2 topline results, +3 more

7 terms

underwritten offering financial

"announced the pricing of an underwritten offering of 29,166,700 shares"

An underwritten offering is when a bank or group of banks agrees to buy all of a company's new shares or bonds and then resell them to outside investors, guaranteeing the company will raise a specific amount of money. It matters to investors because it adds certainty that the funding will close while increasing the number of shares or debt in the market, which can lower the price per share and change each existing owner's ownership percentage—think of a wholesaler buying an entire shipment from a maker before it reaches stores.

series a common stock financial

"29,166,700 shares of its Series A common stock at a price of $6.00"

Series A common stock is a specific class of a company’s ordinary shares issued during an early formal funding round, carrying the ownership rights and voting power tied to that class. For investors it signals an early-stage equity claim with potential upside if the business grows, but also greater risk and typically less liquidity than shares in mature, publicly traded firms—imagine buying a seat on a startup’s team before the company has proven itself.

phase 3 clinical trial medical

"to fund a Phase 3 clinical trial for denifanstat in acne"

A phase 3 clinical trial is a large-scale study that tests a new medical treatment or drug to determine if it is safe and effective for widespread use. It often involves hundreds or thousands of participants and compares the new treatment to existing options or a placebo. For investors, the results of this phase are crucial, as successful outcomes can lead to regulatory approval and commercial success, while failures may halt development.

phase 2 topline results medical

"fund TVB-3567 through Phase 2 topline results"

Preliminary summary data from a mid-stage clinical trial that highlights the main safety and effectiveness findings without the full detailed analysis. Investors care because these topline results act like a short trailer for the drug’s prospects: they quickly signal whether the treatment shows promise, influence the company’s valuation and ability to raise money, and help predict next steps in development or regulatory review.

fasn inhibitor medical

"advance a topical formulation FASN inhibitor to IND submission"

A FASN inhibitor is a drug that blocks the enzyme fatty acid synthase, which cells use to make fatty acids for building membranes and storing energy. Investors care because many cancers and metabolic diseases rely on this pathway, so these inhibitors are studied as potential therapies; success can boost drug-maker value while failures or safety problems can hurt it. Think of it as cutting off a factory’s raw-material supply to slow or stop a growing product line.

ind submission regulatory

"advance a topical formulation FASN inhibitor to IND submission"

An IND submission is an application a drug developer files with a regulatory authority (for example, the U.S. Food and Drug Administration) asking permission to start testing a new medicine in humans. It shows the company’s lab and safety data and a plan for clinical studies; for investors, an accepted IND is like a green light to move from research to trials, reducing development risk and unlocking value milestones.

prospectus supplement regulatory

"A prospectus supplement relating to the offering, and the accompanying prospectus"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN MATEO, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Sagimet Biosciences Inc. (Nasdaq: SGMT), a clinical-stage biopharmaceutical company developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways, today announced the pricing of an underwritten offering of 29,166,700 shares of its Series A common stock at a price of $6.00 per share. The gross proceeds from the offering are expected to be approximately $175.0 million, before deducting underwriting discounts and commissions and other offering expenses. All of the shares in the offering are to be sold by Sagimet. The offering is expected to close on or about April 28, 2026, subject to the satisfaction of customary closing conditions.

The financing included participation from new and existing investors, including Balyasny Asset Management, Blue Owl Healthcare Opportunities, BVF Partners L.P., Caligan Partners, Coastlands Capital, Farallon Capital Management, Great Point Partners, LLC, Woodline Partners LP and a Large Mutual Fund.  

Leerink Partners, TD Cowen, Guggenheim Securities and Oppenheimer & Co. are acting as joint bookrunning managers for the offering. Canaccord Genuity, H.C. Wainwright & Co. and Jones are acting as co-lead managers for the offering.

Sagimet intends to use the net proceeds from the offering, together with its existing cash, cash equivalents and marketable securities, to fund a Phase 3 clinical trial for denifanstat in acne, fund TVB-3567 through Phase 2 topline results, advance a topical formulation FASN inhibitor to IND submission and for general corporate purposes, including additional clinical development, working capital and operating expenses. The Company currently expects that its existing cash and cash equivalents, together with the proceeds from the offering, will fund its acne programs through 2028 and the readout of the Company’s planned denifanstat Phase 3 clinical trial in moderate to severe acne.

A shelf registration statement on Form S-3 (File No. 333-281582) relating to these shares was filed with the Securities and Exchange Commission (the “SEC”) and declared effective on August 26, 2024. A prospectus supplement relating to the offering, and the accompanying prospectus, will be filed with the SEC. When available, copies of the prospectus supplement and accompanying prospectus may also be obtained from the offices of Leerink Partners LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, MA 02109, by telephone at (800) 808-7525, ext. 6105, or by email at syndicate@leerink.com; TD Securities (USA) LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717 or by email at TDManualrequest@broadridge.com; or Guggenheim Securities, LLC, Attention: Equity Syndicate Department, 330 Madison Avenue, 8th Floor, New York, NY 10017, by telephone at (212) 518-9544, or by email at GSEquityProspectusDelivery@guggenheimpartners.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these shares, nor will there be any sale of these shares in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state, province, territory or other jurisdiction.

About Sagimet Biosciences

Sagimet is a clinical-stage biopharmaceutical company developing novel FASN inhibitors designed to target dysfunctional metabolic and fibrotic pathways in conditions resulting from the overproduction of the fatty acid, palmitate. FASN is a regulator of lipid synthesis, and a key pathway implicated in multiple diseases, such as acne, MASH and certain FASN-dependent tumor types.

Forward-Looking Statements

This press release contains forward-looking statements. Investors are cautioned not to place undue reliance on these forward-looking statements, including, without limitation, statements regarding the satisfaction of customary closing conditions relating to the offering and sale of shares, Sagimet’s ability to complete the offering, the anticipated gross proceeds from the offering, the intended use of the proceeds from the offering and Sagimet’s cash runway including the proceeds from the offering. Each forward-looking statement is subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied in such statement. Applicable risks and uncertainties include those related to market conditions and satisfaction of customary closing conditions related to the offering and other risks and uncertainties described under the heading “Risk Factors” in documents Sagimet files from time to time with the SEC. There can be no assurance as to whether the offering may be completed. These forward-looking statements speak only as of the date of this press release. Factors or events that could cause Sagimet’s actual results to differ may emerge from time to time, and it is not possible for Sagimet to predict all of them. Sagimet undertakes no obligation to update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by applicable law.

Investor Contact:
Joyce Allaire
LifeSci Advisors
JAllaire@LifeSciAdvisors.com

Media Contact:
Maggie Whitney
LifeSci Communications
mwhitney@lifescicomms.com

FAQ

What did Sagimet Biosciences (SGMT) announce on April 27, 2026?

Sagimet priced an underwritten offering of 29,166,700 Series A shares at $6.00 per share. According to the company, gross proceeds are expected to be approximately $175.0 million, with closing on or about April 28, 2026.

How many shares and at what price did SGMT offer in the April 2026 financing?

SGMT offered 29,166,700 Series A shares at $6.00 per share. According to the company, the offering yields roughly $175.0 million in gross proceeds before fees and expenses.

What will the $175 million in proceeds fund for SGMT (Nasdaq: SGMT)?

Proceeds will fund a Phase 3 denifanstat acne trial and advance TVB-3567 to Phase 2 topline results. According to the company, funds also support a topical FASN IND and general corporate purposes.

When is the SGMT offering expected to close and what conditions apply?

The offering is expected to close on or about April 28, 2026, subject to customary closing conditions. According to the company, closing depends on satisfaction of underwriting and regulatory conditions.

How will the SGMT offering affect existing shareholders?

The company is selling all offered shares, which will dilute existing shareholders proportionally. According to the company, actual dilution depends on total shares outstanding after the offering and net proceeds.

Where can investors obtain the SGMT prospectus supplement for the offering?

Copies of the prospectus supplement will be filed with the SEC and are available from lead managers named in the filing. According to the company, contact information for syndicate desks is provided for prospectus requests.